Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare – Advanced Specialty in Oncology, shared a post on LinkedIn:
“CAR-T Cells for Solid Tumors: Progress and Barriers.
CAR-T cell therapy has transformed the management of hematologic malignancies. Translation to solid tumors remains challenging.
Key barriers include tumor antigen heterogeneity, limited trafficking and persistence of CAR-T cells, and an immunosuppressive tumor microenvironment.
Current strategies under investigation aim to improve efficacy through:
- Multi-antigen targeting CAR constructs to address tumor heterogeneity.
- Armored CAR-T cells engineered to resist immunosuppressive signals.
- Combination approaches with checkpoint inhibitors or other immunomodulatory therapies.
Early clinical signals are encouraging, but durable activity across solid tumors remains limited. Critical questions persist regarding optimal antigen selection, safety, and strategies to overcome tumor microenvironment resistance.
Will multi-targeted and armored CAR designs translate into clinically meaningful outcomes in solid tumors?
Med CellPress.”
Title: Current state of CAR-T cell therapies for solid tumors
Authors: Reginaldo Rosa, Jiangyue Liu, Cathy Lu, Mohamed Abou-el-Enein, John P. Murad, Saul J. Priceman
Read The Full Article
Other articles about CAR-T Cells on OncoDaily.
